<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00357214</url>
  </required_header>
  <id_info>
    <org_study_id>R01AR052322</org_study_id>
    <secondary_id>R01AR052322</secondary_id>
    <nct_id>NCT00357214</nct_id>
  </id_info>
  <brief_title>Effect of Potassium Bicarbonate Supplementation on Bone and Muscle in Older Adults</brief_title>
  <official_title>Effect of Potassium Bicarbonate on Bone and Muscle</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tufts University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Tufts University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      There is increasing evidence that the acid-base balance of diet plays an important role in
      the health of bones and muscles. An excess of acid in the body can result in calcium loss and
      muscle breakdown. Potassium bicarbonate, a base supplement, can neutralize acid within the
      body. The purpose of this study is to determine the effectiveness of potassium and
      bicarbonate, alone and combined, at reducing bone loss and preventing muscle wasting in older
      adults.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The typical American diet of dairy products, grains, and meats results in excess acid
      build-up in the body. The kidney is often unable to remove this excess acid quickly enough,
      resulting in mildly elevated blood acidity. In an attempt to neutralize the acidity, the body
      releases calcium from its bones. Over time, however, this calcium loss can lead to decreased
      bone density and possibly osteoporosis. Excess acid in the body also stimulates the breakdown
      of muscle. The combination of osteoporosis and reduced muscle strength sets the stage for
      falls, fractures, and ultimately functional decline. At least 30% of older adults fall once a
      year and, of those falls, 5% result in fractures. Preserving muscle mass and strength is an
      effective way to lower the risk of falling and to maintain independence among older people.
      Potassium bicarbonate is a base supplement that can neutralize acid. The purpose of this
      study is to determine the effectiveness of potassium and bicarbonate, alone and combined, at
      reducing bone loss and preventing muscle wasting in older adults.

      This study will last 3 months. Participants will be randomly assigned to one of four
      treatment groups:

        -  Group 1 will receive potassium bicarbonate supplements

        -  Group 2 will receive potassium chloride supplements

        -  Group 3 will receive sodium bicarbonate supplements

        -  Group 4 will receive placebo supplements

      All participants will take three pills of their assigned supplement after each meal; this
      will occur on a daily basis throughout the study. Participants will also take a multivitamin
      and a 600-mg calcium tablet daily. Participants will not be required to alter their usual
      diet in any way, but they will be requested to not take their usual calcium and vitamin D
      supplements during the study. Study visits will occur on Days 1, 21, 49, and 84. Days 1 and
      84 study visits will include a review of medical history and physical activity, blood
      collection, and evaluation of weight, blood pressure, calcium absorption, and muscle
      function. Collection of both a 24-hour urine sample and a calendar depicting compliance with
      the supplement schedule will also occur at these two visits. The other study visits, on Days
      21 and 49, may include blood collection, calendar compliance checking, and weight and blood
      pressure measurements. Supplements will be handed out on Days 1, 21, and 49.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2006</start_date>
  <completion_date type="Actual">April 2008</completion_date>
  <primary_completion_date type="Actual">April 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Biochemical Markers of Bone Turnover</measure>
    <time_frame>3 month change in 24-hr urine values</time_frame>
    <description>Change in 24-hr urinary N-telopeptide/creatinine measured at baseline and 3 months</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">171</enrollment>
  <condition>Osteoporosis</condition>
  <condition>Sarcopenia</condition>
  <arm_group>
    <arm_group_label>potassium bicarbonate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive potassium bicarbonate in dosage of 67.5 mmol/d. This compound has no other name.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sodium bicarbonate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive sodium bicarbonate in dosage of 67.5 mmol/d. This compound has no other name.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Potassium chloride</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive potassium chloride in dosage of 67.5 mmol/d. This compound has no other name.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>microcrystalline cellulose</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive placebo is microcrystalline cellulose. This compound has no other name.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Potassium Bicarbonate</intervention_name>
    <description>67.5 mmol/d given as three tablets after each meal, with a full glass of water</description>
    <arm_group_label>potassium bicarbonate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Sodium Bicarbonate</intervention_name>
    <description>67.5 mmol/d given as three tablets after each meal, with a full glass of water</description>
    <arm_group_label>Sodium bicarbonate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Potassium Chloride</intervention_name>
    <description>67.5 mmol/d given as three tablets after each meal, with a full glass of water</description>
    <arm_group_label>Potassium chloride</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>placebo (microcrystalline cellulose)</intervention_name>
    <description>Given as three tablets after each meal, with a full glass of water</description>
    <arm_group_label>microcrystalline cellulose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Body mass idex less than 35

          -  Not currently on a weight gain or weight loss diet

          -  Willing to maintain usual level of physical activity

          -  Willing to refrain from taking own calcium supplements, antacids, or salt substitutes

        Exclusion Criteria:

          -  Vegetarian

          -  Use of glucocorticoids for more than 10 days in the 3 months prior to study entry

          -  Use of estrogen, raloxifene, or calcitonin in the 6 months prior to study entry

          -  Use of bisphosphonate or teriparatide in the 2 years prior to study entry

          -  Current use of diuretics, nonsteroidal anti-inflammatory drugs (NSAIDS),
             beta-blockers, anabolic drugs (steroids or other), angiotensin converting enzyme (ACE)
             inhibitors, or angiotensin receptor blockers (ARBs)

          -  Renal disease, including kidney stones in the 5 years prior to study entry or
             creatinine clearance less than 50 ml/min/1.73 m2 of body surface area

          -  Hyperparathyroidism

          -  Untreated thyroid disease

          -  Significant immune disorder

          -  Current unstable heart disease

          -  Active malignancy or cancer therapy in the year prior to study entry

          -  24-hour urine calcium levels greater than 300 mg/d after 1 week of being off calcium
             supplements

          -  Hypertension, congestive heart failure, arrythmias, or myocardial infarction in the 12
             months prior to study entry

          -  On a salt-restricted diet

          -  Bone density total hip T score of less than -2.5

          -  Abnormal serum calcium

          -  Alkaline phosphatase levels greater than 10% above the upper end of the reference
             range

          -  Adrenal insufficiency, primary aldosteronism, or Bartter's syndrome

          -  Diabetes mellitus

          -  Alcohol use exceeding two drinks/day

          -  Peptic ulcers or esophageal stricture

          -  Screening serum 25(OH)D levels below 16 ng/ml
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bess Dawson-Hughes, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tufts Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Dawson-Hughes B, Harris SS, Palermo NJ, Castaneda-Sceppa C, Rasmussen HM, Dallal GE. Treatment with potassium bicarbonate lowers calcium excretion and bone resorption in older men and women. J Clin Endocrinol Metab. 2009 Jan;94(1):96-102. doi: 10.1210/jc.2008-1662. Epub 2008 Oct 21.</citation>
    <PMID>18940881</PMID>
  </results_reference>
  <results_reference>
    <citation>Dawson-Hughes B, Castaneda-Sceppa C, Harris SS, Palermo NJ, Cloutier G, Ceglia L, Dallal GE. Impact of supplementation with bicarbonate on lower-extremity muscle performance in older men and women. Osteoporos Int. 2010 Jul;21(7):1171-9. doi: 10.1007/s00198-009-1049-0. Epub 2009 Sep 1.</citation>
    <PMID>19727904</PMID>
  </results_reference>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>July 26, 2006</study_first_submitted>
  <study_first_submitted_qc>July 26, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 27, 2006</study_first_posted>
  <results_first_submitted>September 18, 2019</results_first_submitted>
  <results_first_submitted_qc>January 22, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">February 5, 2020</results_first_posted>
  <last_update_submitted>February 4, 2020</last_update_submitted>
  <last_update_submitted_qc>February 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tufts University</investigator_affiliation>
    <investigator_full_name>Bess Dawson-Hughes</investigator_full_name>
    <investigator_title>Senior Scientist</investigator_title>
  </responsible_party>
  <keyword>bone turnover</keyword>
  <keyword>calcium excretion</keyword>
  <keyword>nitrogen excretion</keyword>
  <keyword>potassium bicarbonate</keyword>
  <keyword>muscle loss</keyword>
  <keyword>muscle atrophy</keyword>
  <keyword>bone loss</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
    <mesh_term>Sarcopenia</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Potassium Bicarbonate</title>
          <description>Participants will receive potassium bicarbonate in dosage of 67.5 mmol/d. This compound has no other name.
Potassium Bicarbonate: 67.5 mmol/d given as three tablets after each meal, with a full glass of water</description>
        </group>
        <group group_id="P2">
          <title>Sodium Bicarbonate</title>
          <description>Participants will receive sodium bicarbonate in dosage of 67.5 mmol/d. This compound has no other name.
Sodium Bicarbonate: 67.5 mmol/d given as three tablets after each meal, with a full glass of water</description>
        </group>
        <group group_id="P3">
          <title>Potassium Chloride</title>
          <description>Participants will receive potassium chloride in dosage of 67.5 mmol/d. This compound has no other name.
Potassium Chloride: 67.5 mmol/d given as three tablets after each meal, with a full glass of water</description>
        </group>
        <group group_id="P4">
          <title>Microcrystalline Cellulose</title>
          <description>Participants will receive placebo is microcrystalline cellulose. This compound has no other name.
placebo (microcrystalline cellulose): Given as three tablets after each meal, with a full glass of water</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="43"/>
                <participants group_id="P2" count="43"/>
                <participants group_id="P3" count="42"/>
                <participants group_id="P4" count="43"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="39"/>
                <participants group_id="P2" count="39"/>
                <participants group_id="P3" count="42"/>
                <participants group_id="P4" count="42"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Potassium Bicarbonate</title>
          <description>Participants will receive potassium bicarbonate in dosage of 67.5 mmol/d. This compound has no other name.
Potassium Bicarbonate: 67.5 mmol/d given as three tablets after each meal, with a full glass of water</description>
        </group>
        <group group_id="B2">
          <title>Sodium Bicarbonate</title>
          <description>Participants will receive sodium bicarbonate in dosage of 67.5 mmol/d. This compound has no other name.
Sodium Bicarbonate: 67.5 mmol/d given as three tablets after each meal, with a full glass of water</description>
        </group>
        <group group_id="B3">
          <title>Potassium Chloride</title>
          <description>Participants will receive potassium chloride in dosage of 67.5 mmol/d. This compound has no other name.
Potassium Chloride: 67.5 mmol/d given as three tablets after each meal, with a full glass of water</description>
        </group>
        <group group_id="B4">
          <title>Microcrystalline Cellulose</title>
          <description>Participants will receive placebo is microcrystalline cellulose. This compound has no other name.
placebo (microcrystalline cellulose): Given as three tablets after each meal, with a full glass of water</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="43"/>
            <count group_id="B2" value="43"/>
            <count group_id="B3" value="42"/>
            <count group_id="B4" value="43"/>
            <count group_id="B5" value="171"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>participant age</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="43"/>
                    <count group_id="B2" value="43"/>
                    <count group_id="B3" value="42"/>
                    <count group_id="B4" value="43"/>
                    <count group_id="B5" value="171"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62.2" spread="7.6"/>
                    <measurement group_id="B2" value="62.6" spread="7.6"/>
                    <measurement group_id="B3" value="63.4" spread="7.7"/>
                    <measurement group_id="B4" value="63.3" spread="7.7"/>
                    <measurement group_id="B5" value="62.9" spread="7.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="43"/>
                    <count group_id="B2" value="43"/>
                    <count group_id="B3" value="42"/>
                    <count group_id="B4" value="43"/>
                    <count group_id="B5" value="171"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="24"/>
                    <measurement group_id="B4" value="25"/>
                    <measurement group_id="B5" value="97"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="18"/>
                    <measurement group_id="B5" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="43"/>
                    <count group_id="B2" value="43"/>
                    <count group_id="B3" value="42"/>
                    <count group_id="B4" value="43"/>
                    <count group_id="B5" value="171"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="42"/>
                    <measurement group_id="B4" value="43"/>
                    <measurement group_id="B5" value="171"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Biochemical Markers of Bone Turnover</title>
        <description>Change in 24-hr urinary N-telopeptide/creatinine measured at baseline and 3 months</description>
        <time_frame>3 month change in 24-hr urine values</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Potassium Bicarbonate</title>
            <description>Participants will receive potassium bicarbonate in dosage of 67.5 mmol/d. This compound has no other name.
Potassium Bicarbonate: 67.5 mmol/d given as three tablets after each meal, with a full glass of water</description>
          </group>
          <group group_id="O2">
            <title>Sodium Bicarbonate</title>
            <description>Participants will receive sodium bicarbonate in dosage of 67.5 mmol/d. This compound has no other name.
Sodium Bicarbonate: 67.5 mmol/d given as three tablets after each meal, with a full glass of water</description>
          </group>
          <group group_id="O3">
            <title>Potassium Chloride</title>
            <description>Participants will receive potassium chloride in dosage of 67.5 mmol/d. This compound has no other name.
Potassium Chloride: 67.5 mmol/d given as three tablets after each meal, with a full glass of water</description>
          </group>
          <group group_id="O4">
            <title>Microcrystalline Cellulose</title>
            <description>Participants will receive placebo is microcrystalline cellulose. This compound has no other name.
placebo (microcrystalline cellulose): Given as three tablets after each meal, with a full glass of water</description>
          </group>
        </group_list>
        <measure>
          <title>Biochemical Markers of Bone Turnover</title>
          <description>Change in 24-hr urinary N-telopeptide/creatinine measured at baseline and 3 months</description>
          <units>nmol/mmol</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="39"/>
                <count group_id="O3" value="42"/>
                <count group_id="O4" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.25" spread="1.75"/>
                    <measurement group_id="O2" value="-3.36" spread="1.68"/>
                    <measurement group_id="O3" value="-0.14" spread="1.71"/>
                    <measurement group_id="O4" value="0.5" spread="1.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Potassium Bicarbonate</title>
          <description>Participants will receive potassium bicarbonate in dosage of 67.5 mmol/d. This compound has no other name.
Potassium Bicarbonate: 67.5 mmol/d given as three tablets after each meal, with a full glass of water</description>
        </group>
        <group group_id="E2">
          <title>Sodium Bicarbonate</title>
          <description>Participants will receive sodium bicarbonate in dosage of 67.5 mmol/d. This compound has no other name.
Sodium Bicarbonate: 67.5 mmol/d given as three tablets after each meal, with a full glass of water</description>
        </group>
        <group group_id="E3">
          <title>Potassium Chloride</title>
          <description>Participants will receive potassium chloride in dosage of 67.5 mmol/d. This compound has no other name.
Potassium Chloride: 67.5 mmol/d given as three tablets after each meal, with a full glass of water</description>
        </group>
        <group group_id="E4">
          <title>Microcrystalline Cellulose</title>
          <description>Participants will receive placebo is microcrystalline cellulose. This compound has no other name.
placebo (microcrystalline cellulose): Given as three tablets after each meal, with a full glass of water</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>gastrointestinal symptoms</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="43"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="42"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Bess Dawson-Hughes</name_or_title>
      <organization>Tufts University</organization>
      <phone>617 556 3066 ext 6175100519</phone>
      <email>bess.dawson-hughes@tufts.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

